Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
Type:
Application
Filed:
July 2, 2018
Publication date:
November 8, 2018
Applicant:
The United States of America,as represented by the Secretary,Department of Helath and Human Services
Inventors:
Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
Type:
Application
Filed:
September 20, 2017
Publication date:
January 11, 2018
Applicant:
The United States of America,as represented by the Secretary, Department of Helath and Human Service
Inventors:
Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley, Ching-Juh Lai
Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
Type:
Grant
Filed:
September 13, 2012
Date of Patent:
December 8, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Helath and Human Services
Inventors:
Ira H. Pastan, Masanori Onda, Wenhai Liu